The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to ...

Drugs aimed at slowing Alzheimer's disease progression "make no meaningful difference to patients" while raising the risk of brain swelling and bleeding, a new review has claimed. However, charities ...

The review by researchers at Anglia Ruskin University in the UK looked at 30 published studies conducted in cell cultures and ...

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes, and premature death over a sustained period of time. Researchers from Anglia Ruskin University ...

I have been following the story here of the newest Alzheimers drugs, the first to show that they can actually slow the ...

The Food and Drug Administration granted a quick review of three experimental psychedelic drugs meant to treat major ...

With Health Secretary Robert F. Kennedy Jr. aiming to rein in the use of psychiatric drugs, psychiatrists are preemptively ...

A fascinating new book looks at how experimentation with psychedelics altered the course of American psychiatry.

A major review of 30 preclinical studies suggests GLP-1 receptor agonists, widely used for diabetes and weight loss, may reduce key Alzheimer’s disease proteins. The drugs lowered amyloid-beta in most ...

Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental ...

The FDA is fast tracking its review of two psychedelic drugs for mental health treatments.

A day after the DOJ said it would ease restrictions on medical marijuana, the FDA moves to fast-track some experimental ...